Biochemical Analysis of Potential Sites for Protein 4.1-mediated Anchoring of the Spectrin-Actin Skeleton to the Erythrocyte Membrane*

Ryan F. Workman and Philip S. LowDagger

From the Department of Chemistry, Purdue University, West Lafayette, Indiana 47907-1393

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Erythrocyte protein 4.1 has been hypothesized to link the spectrin-actin junctional complex directly to the cytoplasmic domain of glycophorin C, but this bridging function has never been directly demonstrated. Because an alternative protein-mediated bridge between the junctional complex and the cytoplasmic domain of band 3 is also plausible, we have undertaken to characterize the membrane sites to which protein 4.1 can anchor the spectrin and actin skeleton. We demonstrate that proteolytic removal of the cytoplasmic domain of band 3 has minimal effect on the ability of protein 4.1 to promote 125I-labeled spectrin and actin binding to KI-stripped erythrocyte membrane vesicles. We also show that quantitative blockade of all band 3 sites with either monoclonal or polyclonal antibodies to band 3 is equally ineffective in preventing protein 4.1-mediated association of spectrin and actin with the membrane. In contrast, obstruction of protein 4.1 binding to its docking site on the cytoplasmic pole of glycophorin C is demonstrated to reduce the same protein 4.1 bridging function by ~85%. We conclude from these data that (i) glycophorin C contributes the primary anchoring site of the protein 4.1-mediated bridge to the spectrin-actin skeleton; (ii) band 3 is incapable of serving the same function; and (iii) additional minor protein 4.1 bridging sites may exist on the human erythrocyte membrane.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Spectrin, actin, and protein 4.1 form the bulk of the protein network that underlies and stabilizes the human erythrocyte membrane (1-7). Polymerization of spectrin with actin into a two-dimensional network is strongly dependent on protein 4.1, an ~78-kDa polypeptide that binds avidly to the beta  subunit of spectrin (8-13) and thereby forms a calmodulin-dependent binding site for actin (14). The approximate stoichiometry of this ternary complex, as estimated from the composition of the dense gel that rapidly forms when protein 4.1 is added to a solution of spectrin and actin, is 1:2:1 of spectrin:actin:protein 4.1 (15, 16). Not surprisingly, defects in the structure or level of expression of protein 4.1 in erythrocytes result in fragile, abnormally shaped cells (17-19). More importantly, when membrane mechanical instability arises from the absence of protein 4.1, the membrane fragility can be corrected by resealing either intact protein 4.1 or its spectrin-actin binding domain into the defective erythrocytes (20).

In addition to its association with spectrin and actin, protein 4.1 also interacts with at least two prominent integral proteins of the red cell membrane. The more avid of these membrane ligands is glycophorin C, which binds protein 4.1 with a KD ~50 nM and provides up to <FR><NU>1</NU><DE>3</DE></FR> of its total anchoring sites on KI-IOVs1 (21-23). P55, a protein comprised of several classical signal transduction domains (24, 25), is thought to significantly stabilize this association (26-28). Of lower affinity than glycophorin C is the interaction of protein 4.1 with band 3, the anion transport protein that also links ankyrin to the red cell membrane. Band 3 associates with protein 4.1 approximately 30-fold less avidly than glycophorin C; however, the anion transporter may also provide up to twice the number of membrane binding sites as glycophorin C (23, 29, 30). In addition to glycophorin C and band 3, protein 4.1 is also known to interact with anionic lipids, especially phosphatidylserine and phosphatidylinositol 4,5-bisphosphate (31-35).

With both the lipid bilayer and membrane skeletal attachment sites for protein 4.1 established, the question naturally arises as to which protein 4.1 sites can be simultaneously occupied, i.e. from which membrane sites might protein 4.1 form a bridge to the spectrin-actin skeleton. Evidence in support of a glycophorin C linkage to the membrane skeleton includes the following: (i) retention of glycophorin C in detergent-extracted membrane skeletons correlates with the content of protein 4.1 in the same skeletons under a variety of conditions (36, 37); (ii) addition of protein 4.1 to protein 4.1-deficient erythrocytes converts glycophorin C from a detergent-soluble membrane protein to a skeletally linked membrane protein (37); and (iii) migration of glycophorin C in membrane distentions of protein 4.1-deficient cells follows the behavior of a freely diffusing membrane protein, whereas migration in similar tethers of normal membranes conforms to the distribution pattern of the spectrin-actin skeleton (38). Taken together, these data argue that some type of protein 4.1-mediated bridge between glycophorin C and the spectrin-actin skeleton must exist. Nevertheless, the hypothesized physical linkage has never been directly demonstrated in any defined biochemical system.

Data exploring the possible role of band 3 in anchoring a protein 4.1 bridge to the membrane skeleton are essentially nonexistent. Analogous studies on the migration and extractability of band 3 in protein 4.1-deficient membranes are obviously meaningless, because band 3 is independently linked via ankyrin to the spectrin-actin skeleton (1). Furthermore, no direct binding studies have ever been conducted to examine whether band 3-linked protein 4.1 can simultaneously bind spectrin and actin. Consequently, we have undertaken to characterize the direct protein 4.1-mediated bridging of spectrin-actin complexes to band 3 and glycophorin C in KI-stripped inside-out erythrocyte membrane vesicles. We report here that glycophorin C, as expected, constitutes the primary attachment site of the protein 4.1-tethered spectrin-actin skeleton. We also demonstrate that band 3 is unable to serve an analogous bridging function.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Protein Purifications-- Protein 4.1 was purified by a novel purification protocol (39) based on the method of Tyler et al. (40). Spectrin and actin were extracted from red cell membranes using low ionic strength buffer, as described by Bennett (41), except the membranes were prepared in the presence of 2 mM MgCl2. Spectrin and actin were subsequently concentrated by dehydration through a dialysis membrane against polyethylene glycol, and the concentrated proteins were labeled with 125I Bolton-Hunter reagent (see below). Spectrin and actin were then transferred to binding buffer (10 mM HEPES, 130 mM KCl, 20 mM NaCl, 2 mM MgCl2, pH 7.4) and stored at 4 °C until used.

Membrane Preparations-- IOVs were prepared essentially as described elsewhere (41), except during removal of spectrin and actin the IOVs were incubated at 37 °C for 30 min in a minimum of 100 volumes of extraction buffer (0.5 mM EDTA, 1 mM dithiothreitol, pH 8.0). KI-stripped IOVs were prepared, when desired, by incubating the IOVs at 37 °C for 30 min in 50 volumes of KI buffer (2 M KI, 25 mM Na2HPO4, 1 mM EDTA, pH 7.6) prior to dilution with an equal volume of double distilled water and centrifugation at 23,400 × g for 1 h. The resulting membranes were washed two times with lysis buffer (5 mM Na2HPO4, 1 mM EDTA, pH 8.0) before resuspension in binding buffer. Membranes showed no aggregation upon resuspension in binding buffer.

125I Protein Labeling-- All 125I-labeled proteins were prepared by the method of Bennett (41) with minor modifications. Briefly, spectrin and actin were labeled in labeling buffer (20 mM Na2HPO4, 100 mM NaCl, 1 mM EDTA, pH 7.6) at a concentration of 8.2 mg/ml. Following labeling, the proteins were extensively dialyzed at 4 °C against binding buffer to remove unreacted label. Protein stocks of the appropriate concentration were then prepared by dilution with binding buffer just before use.

Antibodies-- Polyclonal antibodies were raised in rabbits against a synthetic glycophorin C peptide comprising residues 85-98, according to published procedures (42). The antibody was purified using the synthetic peptide as an affinity ligand. A monoclonal antibody (m00-10) directed against the N-terminal 10 residues of the cytoplasmic domain of band 3, and polyclonal antibodies against the entire cytoplasmic domain of band 3 were also prepared, as described previously (43). Nonspecific IgG was partially purified by ammonium sulfate precipitation of rabbit preimmune serum followed by DEAE chromatography.

Binding Assays-- For determination of protein 4.1 polymerization with spectrin and actin, 30 µg/ml protein 4.1 was added to increasing concentrations of 125I-labeled spectrin and actin in binding buffer, and the solution was allowed to incubate for 3 h at 4 °C. After layering onto 0.25 ml of a 20% sucrose solution in binding buffer, the 0.4-ml microcentrifuge tubes were centrifuged at 49,000 × g for 40 min. The tubes were then frozen in liquid N2, and the tips containing the pelleted protein complexes were severed and counted in a gamma counter.

Measurement of protein 4.1 binding to IOV and KI-IOV membranes was conducted as described above, only increasing concentrations of 125I-labeled protein 4.1 were incubated for 3 h at 4 °C with 50 µg/ml membrane protein prior to separation of the free 125I-protein 4.1 from bound 125I-protein 4.1 on the above sucrose cushion.

Evaluation of protein 4.1-mediated bridging of 125I-labeled spectrin and actin to KI-IOVs required a new method for cleanly distinguishing the easily pelleted spectrin-actin-protein 4.1 copolymer (that forms whenever free protein 4.1, spectrin, and actin are present together) from the membrane-associated form of the same ternary complex. Unfortunately, due to the large size heterogeneity of the copolymer population, neither sucrose gradient sedimentation nor gel filtration chromatography was found capable of quantitatively separating bound from free ternary complexes. Therefore, an assay was designed that avoided formation of free spectrin-actin-protein 4.1 copolymer, allowing the membrane-bound spectrin and actin to be quantitated by simple pelleting. For this purpose, KI-IOVs (45 µg/ml) were incubated in binding buffer for 16 h at 4 °C with or without excess competing antibody to band 3 or glycophorin C. Protein 4.1 (50 µg/ml) was then allowed to bind unoccupied sites on these membranes by incubating the protein with the blocked membranes for 4 h at 4 °C. The resulting membranes were washed 3 × in binding buffer followed each time by pelleting for 15 min at 35,000 × g to remove unbound protein 4.1. Quantitative extraction of free protein 4.1 was assured by demonstrating the inability of the final wash supernatant to promote sedimentation of any 125I-labeled spectrin and actin. The washed membranes were then incubated for 4 h at 0 °C with 125I-labeled spectrin and actin, after which the membranes were washed twice by centrifugation and counted in a gamma counter to determine the content of bound skeletal complex.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Characterization of Components and Binding Interactions-- Because the functional properties of a protein 4.1 preparation can be measurably affected by contaminating proteins (e.g. p55, Ref. 28) and denatured or nonfunctional protein 4.1 domains (39), we felt compelled to establish the functional integrity of the protein 4.1 we had purified before beginning to evaluate its membrane bridging properties. As shown in Fig. 1A, the protein 4.1 employed in these studies actively polymerizes spectrin and actin (Fig. 1C, lane D) into pelletable polymers, indicating that the protein 4.1 retains its affinity for the membrane skeleton. The complementary affinity of protein 4.1 for erythrocyte membrane sites is shown in Fig. 1B, where protein 4.1 is seen to bind KI-IOVs (Fig. 1C, lane B) with equal affinity to previously published preparations (22, 23). The reduced binding to nonstripped IOVs (Fig. 1B) confirms the specificity of the protein 4.1 interaction, since many of the membrane sites in IOVs are occupied by endogenous protein 4.1. 


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Characterization of the components employed in the protein 4.1 binding assays. A, stimulation of spectrin-actin copolymerization by protein 4.1. Increasing concentrations of a mixture of 125I-labeled spectrin and actin were incubated for 3 h at 4 °C with (black-diamond ) or without (diamond ) 30 µg/ml protein 4.1. Copolymerized material was then isolated and counted by pelleting the dense complex through a 20% sucrose cushion, as described under "Experimental Procedures." Data points represent the average of two samples ± S.D. In some cases, the error bars do not extend beyond the dimensions of the data symbols. B, evaluation of 125I-protein 4.1 binding to IOVs and KI-IOVs. Increasing concentrations of 125I-labeled protein 4.1 were incubated with 50 µg/ml KI-IOVs (black-diamond ) or an equivalent number of IOVs (black-square) for 3 h at 4 °C, after which bound protein 4.1 was separated from free protein 4.1 by sedimentation through a 20% sucrose cushion, as described under "Experimental Procedures." All data points were obtained in triplicate. Error bars represent standard deviations from the mean. C, SDS-polyacrylamide gel electrophoresis of proteins and membrane preparations. Lane A, erythrocyte membranes; lane B, KI-IOVs; lane C, trypsin-digested KI-IOVs; lane D, spectrin and actin; lane E, protein 4.1.

To evaluate the ability of protein 4.1 to mediate attachment of the spectrin-actin network to the red cell membrane, protein 4.1 was first allowed to bind KI-stripped IOVs, and after extensive washing to remove unbound protein 4.1, 125I-labeled spectrin and actin (Fig. 1C, lane D) were added to measure protein 4.1-facilitated binding. As shown in Fig. 2, spectrin and actin associated much more extensively with membranes preincubated with protein 4.1 (solid diamonds) than those lacking protein 4.1 (open diamonds). These observations document biochemically that protein 4.1 can indeed function to bridge the spectrin-actin skeleton to the membrane.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Protein 4.1-dependent binding of 125I-labeled spectrin and actin to KI-IOVs and trypsin-digested KI-IOVs. 45 µg/ml KI-IOVs (black-diamond , diamond ) or trypsin-digested KI-IOVs (black-square, square ) were incubated for 4 h at 4 °C in the presence (black-diamond , black-square) or absence (diamond , square ) of 50 µg/ml protein 4.1. After thorough washing to remove unbound protein 4.1, increasing concentrations of 125I-labeled spectrin and actin were allowed to bind. Unbound 125I-spectrin and actin were then separated from membrane-bound material by centrifugation, and the membrane fraction was counted in a gamma counter, as described under "Experimental Procedures." All data points represent the mean ± S.D., where n = 3.

Evaluation of the Role of Band 3 in Anchoring a Protein 4.1 Bridge to the Membrane Skeleton-- To identify the integral membrane protein(s) that participate in the protein 4.1-mediated tether to the spectrin-actin skeleton, several additional studies were conducted. First, the cytoplasmic domain of band 3 was proteolytically removed with trypsin, and the above described protein 4.1 binding and bridging functions were again evaluated. As shown in Fig. 3, 125I-protein 4.1 association with the trypsin-cleaved KI-IOVs was reduced to 45% of normal, consistent with earlier observations that band 3 might contribute up to 60% of the sites on KI-stripped erythrocyte membranes (21, 23, 29-30, 44). Importantly, protein 4.1-mediated bridging of the spectrin-actin complex to the same digested membranes was only slightly altered, displaying somewhat reduced binding at high spectrin-actin concentrations but normal binding at lower concentrations (Fig. 2, solid squares). Since >95% of the band 3 was digested in these membrane preparations (Fig. 1C, lane C), we conclude that band 3 is not a major participant in the protein 4.1-mediated skeletal anchor.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   125I-protein 4.1 binding to KI-IOVs and trypsin-digested KI-IOVs in the presence and absence of antibodies to the protein 4.1 binding site on glycophorin C. 50 µg/ml 125I-protein 4.1 was incubated for 4 h at 4 °C with control KI-IOVs (A), KI-IOVs plus 8.6 mg/ml nonspecific IgG (B), KI-IOVs plus 1.5 mg/ml affinity purified anti-glycophorin C IgG (C), trypsinized KI-IOVs (D), trypsinized KI-IOVs plus 8.6 mg/ml nonspecific IgG (E), or trypsinized KI-IOVs plus 1.5 mg/ml affinity purified anti-glycophorin C IgG (F). Bound and free 125I-protein 4.1 were then separated by pelleting the membranes through a 20% sucrose cushion, after which the bound fraction was counted in a gamma counter. Data shown represent the mean ± S.D. of three separate assays.

To resolve more thoroughly the question of whether band 3 plays even a minor role in anchoring a protein 4.1 bridge to the spectrin-actin network, we directly blocked the protein 4.1 binding sites on band 3 with a monoclonal antibody to the N terminus of band 3, and then we examined the effect of this modification on the interaction of 125I-labeled spectrin and actin with the opsonized KI-IOVs. The monoclonal antibody employed in this study (m00-01) has been shown previously to quantitatively prevent protein 4.1 binding to the cytoplasmic domain of band 3 (44). Furthermore, as observed previously for the proteolytically digested KI-IOVs (Fig. 3), the monoclonal Fab reduces 125I-labeled protein 4.1 binding to KI-IOVs to <50% of control values (Fig. 4). Despite this loss of roughly half of the protein 4.1 binding sites on the membrane, no diminution in protein 4.1-mediated attachment of 125I-labeled spectrin and actin to the membrane was observed (Fig. 5A). Rather, the protein 4.1-facilitated spectrin-actin binding to opsonized KI-IOVs matched the binding isotherm of control KI-IOVs. Similar results were also obtained with a polyclonal antibody to the whole cytoplasmic domain of band 3 (Fig. 5B). Thus, loss of all band 3 sites can be concluded to have no impact on protein 4.1-mediated attachment of the membrane skeleton to the erythrocyte membrane.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of increasing concentrations of the antigen binding fragment (Fab) of a monoclonal IgG to the N terminus of band 3 on 125I-protein 4.1 binding to KI-IOVs. black-diamond , Fab of monoclonal antibody (m00-01) to residues 1-10 of band 3; black-square, nonspecific IgG. Data points presented represent the mean ± S.D., where n = 2.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of anti-band 3 antibodies on protein 4.1-mediated binding of 125I-labeled spectrin and actin to KI-IOVs. KI-IOVs were first incubated for 16 h at 4 °C with or without excess competing antibody to the protein 4.1 binding site on band 3. The opsonized KI-IOVs were then incubated for 4 h at 4 °C with or without 50 µg/ml protein 4.1, and after thorough washing, they were finally incubated for 4 h at 0 °C with increasing concentrations of 125I-labeled spectrin and actin. See "Experimental Procedures" for details. A, analysis of competition from the Fab fragment of the monoclonal antibody (m00-01) to the N terminus of band 3 characterized in Fig. 4. B, analysis of competition from a polyclonal IgG to the intact cytoplasmic domain of band 3. diamond , KI-IOVs incubated with 125I-labeled spectrin and actin; black-diamond , KI-IOVs incubated with protein 4.1 and subsequently with 125I-labeled spectrin and actin; black-square, anti-band 3 blocked KI-IOVs incubated with protein 4.1 and subsequently with 125I-labeled spectrin and actin.

Evaluation of the Role of Glycophorin C in Anchoring a Protein 4.1 Bridge to the Membrane Skeleton-- To determine whether glycophorin C might provide the membrane anchor for the protein 4.1 bridge to the spectrin-actin skeleton, a similar series of studies to those described above was performed with an antibody to glycophorin C. In this case, the antibody was raised against the amino acid sequence identified by two other groups (27, 28) as the protein 4.1 binding site on glycophorin C (Fig. 6A). Not surprisingly, the antibody competitively displaced ~27% of protein 4.1 binding to KI-IOVs and ~66% of the residual protein 4.1 binding to trypsin-digested KI-IOVs (Fig. 3). It can, therefore, be concluded that the antibody effectively prevents protein 4.1 binding to glycophorin C sites on the red cell membrane.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   A, comparison of the amino acid sequences of glycophorin C shown by Hemming et al. (28) and Marfatia et al. (27) to constitute the primary protein 4.1 binding site with the sequence used to raise the polyclonal antipeptide antibody employed in B. B, effect of the antibody to the protein 4.1 docking site on glycophorin C on protein 4.1-mediated spectrin-actin binding to KI-IOVs. All procedures were performed as outlined under "Experimental Procedures" and in the legend to Fig. 5. KI-IOVs were incubated with either affinity purified anti-glycophorin C IgG (bullet ) or buffer only (black-diamond , [diafo]) and then supplemented with purified protein 4.1 (bullet , black-diamond ) prior to incubation with increasing concentrations of 125I-labeled spectrin and actin. Membrane-bound, 125I-labeled spectrin and actin were then determined by gamma counting of the pelleted KI-IOVs. Data points represent the mean ± S.D., where n = 2.

In stark contrast to the effect of anti-band 3 antibodies, the anti-glycophorin C antibody also blocked the majority of protein 4.1-mediated 125I-spectrin and actin binding to the red cell membrane (Fig. 6B). Indeed, ~85% of all bridging sites on the KI-IOVs were eliminated by anti-glycophorin C opsonization. The conclusion, therefore, follows that glycophorin C serves as the primary anchoring site of protein 4.1-mediated tethers to the spectrin and actin skeleton. However, because ~15% of protein 4.1-assisted connections to the membrane skeleton consistently survived competition with anti-glycophorin C, we also propose that an unidentified anchor for protein 4.1 may still remain on the red cell membrane.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Two lines of evidence were presented to demonstrate that band 3 does not participate in a protein 4.1-mediated bridge to the spectrin-actin skeleton. First, monoclonal and polyclonal antibodies to band 3 reduced protein 4.1 binding to KI-IOVs by >50% but had no effect on protein 4.1-mediated association of spectrin and actin with the membrane. Second, tryptic removal of the cytoplasmic domain of band 3, which reportedly does not cleave glycophorin C (22) but may well digest other less prominent protein 4.1 binding sites, reduced protein 4.1-promoted spectrin and actin binding to KI-IOVs only minimally. In fact, in three independent replicates of this experiment, trypsin digestion decreased spectrin and actin binding only at elevated 125I-labeled spectrin and actin concentrations, suggesting an unidentified class of lower affinity sites might have been eliminated by the tryptic proteolysis. In this respect, it is interesting to note that protein 4.1-related polypeptides connect CD44 to the cytoskeleton in nonerythroid cells (45, 46) and that CD44 has been recently shown to bind protein 4.1 in mature erythrocytes.2

There are major discrepancies in the literature over the distribution of protein 4.1 binding sites between band 3 and glycophorin C. Hemming et al. (28) report that ~85% of all sites on stripped IOVs reside on glycophorin C. Cohen and co-workers (21) and Low and co-workers (30) measure only ~<FR><NU>1</NU><DE>3</DE></FR> of the total sites on glycophorin C, the remainder locating primarily on band 3. Although differences in binding assays could account for part of this variability, the majority of the discrepancy likely derives from differences in the stripping procedures used to remove endogenous protein 4.1 from the membranes. Hemming et al. (28) employ 0.1 N NaOH to elute peripheral proteins from their IOV preparations, and although this pH 13 extraction leaves little, if any, peripheral protein on the vesicles, it simultaneously denatures band 3, rendering it incapable of binding ankyrin (47), or participating in the normal dimer-tetramer association equilibrium,3 or even undergoing a normal thermal denaturation transition (48). The advantage of NaOH stripping is that glycophorin C remains functional, and p55, a protein that enhances the affinity of protein 4.1 for glycophorin C, is quantitatively removed. The alternative stripping procedure, i.e. extraction with KI or KCl, leaves band 3 native but unfortunately fails to quantitatively remove p55. Nevertheless, when the distribution of protein 4.1 binding sites among all membrane proteins is to be measured, a nondenaturing stripping protocol must be applied to ensure that the contributions of labile membrane proteins are fairly considered. Under these conditions, a substantial fraction of the protein 4.1 binding sites on red cell membranes clearly reside on band 3.

Given the inability of band 3 to anchor a protein 4.1 linkage to the spectrin-actin network, the question naturally arises as to what purpose the protein 4.1-band 3 association might serve. Our ideas on this matter concur with those of An et al. (49). Briefly, both laboratories have observed that protein 4.1 competes with ankyrin for a site on band 3 (44, 49). Because the band 3-ankyrin-spectrin linkage constitutes the major attachment site of the spectrin-actin skeleton to the bilayer, any protein 4.1-mediated displacement of ankyrin might be expected to destabilize the cell. This has indeed been observed (49), suggesting that the mechanical properties of the erythrocyte membrane might be regulated in part by the distribution of protein 4.1 between glycophorin C and band 3. In this scenario, stimuli that displace protein 4.1 from the junctional complex (e.g. cAMP, Refs. 50 and 51), allowing the protein 4.1 to compete with ankyrin for band 3, might be expected to weaken the membrane's structure, whereas stimuli that promote the opposite translocation would be expected to strengthen it (21, 52).

Finally, it should be noted that ~40% of glycophorin C is free to diffuse laterally in erythrocyte membranes, suggesting that this population of glycophorin C is not skeletally attached (40). Since there are maximally 150,000 copies of glycophorin C per red cell membrane (53), it can be calculated that at most 84,000 of the 200,000 total copies of red cell protein 4.1 will be tethered to glycophorin C. The remainder could be complexed with spectrin-actin but unattached to the lipid bilayer or could be bound to band 3 in place of the usual ankyrin bridge. It would seem, therefore, that protein 4.1 has not evolved to maximize its bridging capabilities to glycophorin C but instead to serve as a broker of membrane stability, where enhanced association with glycophorin C might be induced to increase membrane-skeletal tethers, whereas decreased association with glycophorin C coupled with a rise in interaction with band 3 might be exploited to weaken skeletal interactions. With the many kinases that regulate the association of protein 4.1 with glycophorin C (51, 54), with the spectrin-actin complex (50-51, 55), and with band 3 (21), one can anticipate that protein 4.1 may eventually prove critical to pathways that modulate erythrocyte behavior.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant GM24417.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 765-494-5273; Fax: 765-494-0239; E-mail: lowps{at}omni.cc.purdue.edu.

1 The abbreviations used are: KI-IOVs, KI-stripped inside-out vesicles; IOVs, inside-out vesicles.

2 N. Mohandas, personal communication.

3 H. Van Dort and P. S. Low, personal observations.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Bennett, V. (1989) Biochim. Biophys. Acta 988, 107-121[Medline] [Order article via Infotrieve]
  2. Palek, J., and Lambert, S. (1990) Semin. Hematol. 27, 290-332[Medline] [Order article via Infotrieve]
  3. Morrow, J. S., and Marchesi, V. T. (1981) J. Cell Biol. 88, 463-468[Abstract]
  4. Byers, T. J., and Branton, D. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 6153-6157[Abstract]
  5. Shen, B. W., Josephs, R., and Steck, T. L. (1986) J. Cell Biol. 102, 997-1006[Abstract]
  6. Liu, S. C., Derick, L. H., and Palek, J. (1987) J. Cell Biol. 104, 527-536[Abstract]
  7. Karinch, A. M., Zimmer, W. E., and Goodman, S. R. (1990) J. Biol. Chem. 265, 11833-11840[Abstract/Free Full Text]
  8. Coleman, T., Harris, A., Mische, S., Mooseken, M., and Morrow, J. (1987) J. Cell Biol. 104, 519-526[Abstract]
  9. Becker, P. S., Cohen, C. M., and Lux, S. E. (1986) J. Biol. Chem. 261, 4620-4628[Abstract/Free Full Text]
  10. Becker, P. S., Schwartz, M. A., Morrow, J. S., Lux, S. E. (1990) Eur. J. Biochem. 193, 827-836[Abstract]
  11. Cohen, C. M., and Foley, S. F. (1984) Biochemistry 23, 6091-6098[Medline] [Order article via Infotrieve]
  12. Cohen, C. M., and Langley, R. C., Jr. (1984) Biochemistry 23, 4488-4495[Medline] [Order article via Infotrieve]
  13. Cohen, C. M., and Korsgren, C. (1980) Biochem. Biophys. Res. Commun. 97, 1429-1435[Medline] [Order article via Infotrieve]
  14. Tanaka, T., Kadowaki, K., Lazarides, E., and Sobue, K. (1991) J. Biol. Chem. 266, 1134-1140[Abstract/Free Full Text]
  15. Ungewickell, E., Bennett, P. M., Calvert, R., Ohanian, V., and Gratzer, W. B. (1979) Nature 280, 811-814[Medline] [Order article via Infotrieve]
  16. Pekrun, A., Pinder, J. C., Morris, S. A., Gratzer, W. B. (1989) Eur. J. Biochem. 182, 713-717[Abstract]
  17. Lorenzo, F., Venezia, N. D., Morle, L., Baklouti, F., Alloisio, N., Ducluzeau, M.-T., Roda, L., Lefrancois, P., and Delaunay, J. (1994) J. Clin. Invest. 94, 1651-1656[Medline] [Order article via Infotrieve]
  18. Feo, C. J., Fischer, S., Piau, J. P., Grange, M. J., Tchernia, G. (1980) Nouv. Rev. Fr. Haematol. 22, 315-325[Medline] [Order article via Infotrieve]
  19. Tchernia, G., Mohandas, N., and Shohet, S. B. (1981) J. Clin. Invest. 68, 454-460[Medline] [Order article via Infotrieve]
  20. Discher, D., Parra, M., Conboy, J. G., Mohandas, N. (1993) J. Biol. Chem. 268, 7186-7195[Abstract/Free Full Text]
  21. Danilov, Y. N., Fennell, R., Ling, E., and Cohen, C. M. (1990) J. Biol. Chem. 265, 2556-2562[Abstract/Free Full Text]
  22. Shiffer, K. A., and Goodman, S. R. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 4404-4408[Abstract]
  23. Gascard, P., and Cohen, C. M. (1994) Blood 83, 1102-1108[Abstract/Free Full Text]
  24. Ruff, P., Speicher, D. W., and Chishti, A. H. (1991) Biochemistry 88, 6595-6599
  25. Kim, A. C., Metzenberg, A. B., Sahr, K. E., Marfatia, S. M., Chishti, A. H. (1996) Genomics 31, 223-229[CrossRef][Medline] [Order article via Infotrieve]
  26. Alloisio, N., Venezia, N. D., Rana, A., Andrabi, K., Texier, P., Gilsanz, F., Cartron, J.-P., Delaunay, J., and Chishti, A. H. (1993) Blood 82, 1323-1327[Abstract]
  27. Marfatia, S. M., Lue, R. A., Branton, D., and Chishti, A. H. (1995) J. Biol. Chem. 270, 715-719[Abstract/Free Full Text]
  28. Hemming, N. J., Anstee, D. J., Stariocoff, M. A., Tanner, M. J. A., Mohandas, N. (1995) J. Biol. Chem. 270, 5360-5366[Abstract/Free Full Text]
  29. Pasternack, G. R., Anderson, R. A., Leto, T. L., Marchesi, V. T. (1985) J. Biol. Chem. 260, 3676-3683[Abstract]
  30. Moriyama, R., Lombardo, C. R., Workman, R. F., Low, P. S. (1993) J. Biol. Chem. 268, 10990-10996[Abstract/Free Full Text]
  31. Rybicki, A. C., Heath, R., Lubin, B., and Schwartz, R. S. (1988) J. Clin. Invest. 81, 255-260[Medline] [Order article via Infotrieve]
  32. Cohen, A. M., Liu, S. C., Lawler, J., Derick, L. H., Palek, J. (1988) Biochemistry 27, 614-619[Medline] [Order article via Infotrieve]
  33. Shiffer, K. A., Goerke, J., Düzgünes, N., Feder, J., and Shohet, S. B. (1988) Biochim. Biophys. Acta 937, 269-280[Medline] [Order article via Infotrieve]
  34. Sato, S. B., and Ohnishi, S. (1983) Eur. J. Biochem. 130, 19-25[Abstract]
  35. Anderson, R., and Marchesi, V. (1985) Nature 318, 295-298[Medline] [Order article via Infotrieve]
  36. Mueller, T. J., and Morrison, M. (1986) in Erythrocyte Membranes: Clinical and Experimental Advances (Kruckenberg, W., Eaton, J., and Brewer, G., eds), Vol. 2, pp. 95-108, Alan R. Liss, Inc., New York
  37. Reid, M. E., Takakuwa, Y., Conboy, J., Tchernia, G., and Mohandas, N. (1990) Blood 75, 2229-2234[Abstract]
  38. Discher, D. E., Mohandas, N., and Evans, E. A. (1994) Science 266, 1032-1035[Medline] [Order article via Infotrieve]
  39. Workman, R. F., and Low, P. S. (1998) Protein Expression Purif., 11, in press
  40. Tyler, J. M., Hargreaves, W. R., and Branton, D. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 5192-5196[Abstract]
  41. Bennett, V. (1983) Methods Enzymol. 96, 316-318
  42. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  43. Willardson, B. M., Thevenin, B. J., Harrison, M. L., Kuster, W. M., Benson, M. D., Low, P. S. (1989) J. Biol. Chem. 264, 15893-15899[Abstract/Free Full Text]
  44. Lombardo, C. R., Willardson, B. M., Low, P. S. (1992) J. Biol. Chem. 267, 9540-9546[Abstract/Free Full Text]
  45. Tsukita, S. A., Oishi, K., Sato, N., Sagara, J., Kawai, A., and Tsukita, S. H. (1994) J. Cell Biol. 126, 391-401[Abstract]
  46. Hirao, M., Sato, N., Kondo, T., Yonemura, S., Monden, M., Sasaki, T., Takai, Y., Tsukita, S., and Tsukita, S. (1996) J. Cell Biol. 135, 37-51[Abstract]
  47. Hargreaves, W. R., Giedd, K. N., Verkleij, A., and Branton, D. (1980) J. Biol. Chem. 255, 11965-11972[Abstract/Free Full Text]
  48. Appell, K. C., and Low, P. S. (1982) Biochemistry 21, 2151-2157[Medline] [Order article via Infotrieve]
  49. An, X.-L., Takakuwa, Y., Nunomura, W., Manno, S., and Mohandas, N. (1996) J. Biol. Chem. 271, 33187-33191[Abstract/Free Full Text]
  50. Eder, P. S., Soong, C. J., and Tao, M. (1986) Biochemistry 25, 1764-1770[Medline] [Order article via Infotrieve]
  51. Ling, E., Danilov, Y. N., and Cohen, C. M. (1988) J. Biol. Chem. 263, 2209-2216[Abstract/Free Full Text]
  52. Chao, T. S., and Tao, M. (1991) Biochemistry 30, 10529-10535[Medline] [Order article via Infotrieve]
  53. Smythe, J., Gardner, B., and Anstee, D. J. (1994) Blood 83, 1668-1672[Abstract/Free Full Text]
  54. Pinder, J. C., Gardner, B., and Gratzer, W. B. (1995) Biochem. Biophys. Res. Commun. 210, 478-482[CrossRef][Medline] [Order article via Infotrieve]
  55. Subrahmanyan, G., Bertics, P. J., and Anderson, R. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5222-5226[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.